Services // Clinical Research

QUICK LOOK:

For all Oncology Trials
Contact Michelle Mackenzie, RN, OCN, CRC at 973-436-1755 or [email protected]

For all other Studies
Contact Kelly Ritter, LPN, CCRC at 908-721-5673 or [email protected]

Current active trials are listed below


Service Type Name Description
Cancer Services Breast Breast Cancer Biomarker Sample Collection, Phase None Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol NCT02078570
Cancer Services GU/Prostate PROSPECTIVE EVALUATION OF MEN UNDERGOING STEREOTACTIC BODY RADIATION THERAPY, Phase None PROSPECTIVE EVALUATION OF MEN UNDERGOING STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR PROSTATE CANCER
Cancer Services Hematologic An International, Phase 3, Open-label, Randomized Study of BGB-3111, Phase 3 CHRONIC LYMPHOCYTIC LEUKEMIA: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BeiGene BGB-311-304) NCT03336333
Cancer Services Hematologic A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Phase 2/3 ACUTE MYELOID LEUKEMIA: A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy (Astella – 2215-CJ-0201) NCT02752035
Cancer Services Hematologic A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465, Phase 2 ESSENTIAL THROMBOCYTHEMIA/MYELOFIBROSIS: A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis (Incyte 50465-201) NCT02718300
Cancer Services Hematologic A Phase 3, Randomized Study of Zanubrutinib (BGB-3111), Phase 3 CHRONIC LYMPHOCYTIC LEUKEMIA: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BeiGene BGB-3110305) NCT03734016
Cancer Services Gastrointestinal A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI), Phase 3 A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) with or without Bevacizumab in Adult Patients with Previously Treated Metastatic Colorectal Cancer (Boston Medical (CanStem 303C) NCT02753127
Cancer Services Gastrointestinal A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX, Phase 3 A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (Armo AM0010-301) NCT02923921
Cancer Services Gastrointestinal FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6, Phase 3 FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose-Finding in Phase 1 (Five Prime) NCT03694522
Cancer Services Breast Memory Gel and Shape Combined Cohort, Phase None Memory Gel and Shape Combined Cohort (Glow) (Surgical) NCT02919592
Cancer Services Breast monarchE: Randomized Open-Label, Phase 3 monarchE: Randomized Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy vs. Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast (Lilly) NCT03155997 Cohort 2 is now open and enrolling* (Patients must first be confirmed as not be eligible for cohort 1 in order to be screened for cohort 2) Results from Covance must be available and the result must be ≥20% prior to randomizing the patient for cohort 2 in IWRS)
Cancer Services Gynecologic Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment, Phase 2 Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy (AstraZeneca) NCT02983799 MUST BE BRCA mutated
Cancer Services Breast PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB, Phase 2 PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER (Pfizer C3441020) NCT03499353
Cancer Services Gynecologic Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination, Phase 2 Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination with the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer (MD Anderson – 2014-0944) NCT02397083
Cancer Services Breast Single-Arm, Open Label Phase 1b/2 Study of SGN-LIV1A, Phase 1B/2 Single-Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for the First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple Negative Breast Cancer (Seattle Genetics – SGNLVA-002) Waitlist for Cohort 2 NCT03310957
Cancer Services Hematologic A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Phase 3 FOLLICULAR LYMPHOMA: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma (Pharmacyclics PCYC-1141-CA) 60 Years and older NCT02947347
Cancer Services Hematologic An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab, Phase 2 FOLLICULAR LYMPHOMA: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma (BeiGene BGB 3111-212) NCT03332017
Cancer Services Hematologic A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB (PRT062070), Phase 1/2A FOLLICULAR LYMPHOMA: A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB (PRT062070) IN PATIENTS WITH B-CELL OR T-CELL NON-HODGKIN LYMPHOMA (NHL) (Portola 13-601) NCT01994382 Only FL – Grade 1-3A open
Cancer Services Hematologic A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine, Phase 2/3 DIFFUSE LARGE B-CELL LYMPHOMA: A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND (MorphoSys MOR208C204) NCT02763319
Cancer Services Hematologic A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Vs. R-CHOP, Phase 3 DIFFUSE LARGE B-CELL LYMPHOMA: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Vs. R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ (Denovo DB 102-02) NCT03263026
Cancer Services Hematologic KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Phase 2A/2B ESSENTIAL THROMBOCYTHEMIA/MYELOFIBROSIS: KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Ruxolitinib (Kartos Therapeutics) NCT03662126
Cancer Services Hematologic KRT-232-102: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232, Phase 2A/2B ESSENTIAL THROMBOCYTHEMIA/MYELOFIBROSIS: KRT-232-102: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera (Kartos Therapeutics) NCT03669965
Cancer Services Hematologic Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis or High-Risk Essential Thrombocythemia, Phase None ESSENTIAL THROMBOCYTHEMIA/MYELOFIBROSIS: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis or High-Risk Essential Thrombocythemia or ET Patients receiving ET-Directed Therapy (Incyte MA-MF-401 Most Registry) NCT02953704
Cancer Services COMING SOON! An Investigational Immuno-therapy Study for Safety and Efficacy of Nivolumab, Phase None An Investigational Immuno-therapy Study for Safety and Efficacy of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (Bristol Myers Squibb) NCT02869789
Cancer Services COMING SOON! An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination, Phase 1B/2 An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma (Acerta ACE-LY-003)
Cancer Services COMING SOON! A Phase 1b, Multicenter, Open-Label Study of Acalabrutinib in Combination with Bendamustine and Rituxan, Phase 1B A Phase 1b, Multicenter, Open-Label Study of Acalabrutinib in Combination with Bendamustine and Rituxan or Venetoclax and Rituxan in Subjects with Mantle Cell Lymphoma (Acerta-LY-106)
Cancer Services COMING SOON! A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828, Phase 3 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement
Cancer Services Hematologic A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Study of Bendamustine and Rituximab (BR), Phase 3 MANTLE CELL: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Study of Bendamustine and Rituximab (BR) Alone versus in Combination with Acalabrutinib in Subjects with Previously Untreated Mantle Cell Lymphoma (Acerta ACE-LY-308) NCT02972840
Cancer Services Hematologic Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP), Phase None LUNG: Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer NCT03457415 *Please note that only Stage II/Cohort 1a for patients with >50% PDL score remains open with no restrictions at this time
Cancer Services COMING SOON! G1T38-03: Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib, Phase 1B/2 G1T38-03: Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) (G1T38-03)
Cancer Services Hematologic Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices, Phase None HODGKIN'S DISEASE: Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices (Bristol-Myers Squibb) NCT02856646 Enrolling 2nd + line only
Cancer Services COMING SOON! Multi-Center, Open-Label, Single Arm Study of Gazyva Short Duration Infusion in Patients, Phase None Multi-Center, Open-Label, Single Arm Study of Gazyva Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma (Genentech – MO40597)
Cancer Services Hematologic Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab, Phase 2 LUNG: Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer (Tesaro) NCT03308942 *Please note that only Stage II/Cohort 1a for patients with >50% PDL score remains open with no restrictions at this time
Cancer Services COMING SOON! Phase II, Open-label, two cohort, noncomparative study to assess the efficacy and safety of Alpelisib +ET (Fulvestrant or Letrozole), Phase 2 Phase II, Open-label, two cohort, noncomparative study to assess the efficacy and safety of Alpelisib +ET (Fulvestrant or Letrozole) in patients with PIK3CA-mutant HR+, HER- ABC who has progressed on/after CDK4/6i Treatment (Novartis)
Cancer Services COMING SOON! RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade, Phase 1/2 RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors (Replimune)
Cancer Services COMING SOON! A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab and Rucaparib, Phase 3 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab and RucAparib Combination Switch Maintenance following Front-Line Platinum-based Chemotherapy in Ovarian Cancer Patients (ATHENA)
Cancer Services Hematologic A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202, Phase 2B MANTLE CELL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (TG Therapeutics – UTX-TGR-205) NCT02793583 Mantle Cell Arm only
Cancer Services Breast Wisdom Study, Phase None Currently able to enroll women are 40-74 years old, have no personal history of breast cancer or ductal carcinoma in situ (DCIS), have no history of mastectomy in both breasts and are eligible members of Horizon Blue Cross Blue Shield of New Jersey as of October 2018. Women can participate in WISDOM and be randomly assigned to receive either Annual Screening or Risk-based Screening, with an equal chance of being assigned to either group.
NAVIGATION WE ARE HERE TO HELP YOU! STAY CONNECTED Like Tweet Watch Share Follow Instagram